Replies to post #68565 on Biotech Values

[masterlongevity]

companies without enough cash to bring their products to market.

Stock Product Stage Comments ----- --------------- --------------------- ----------------------------- NTII Viprinex Phase 3 Interim analysis January '09. Stroke Drug, high chance of failure. BPAX Libigel Phase 3 ~2010 Submit Adequate Safety? EPIX Vasovist PDUFA 12/30/08 FDA initial rejected saying 2 more studies needed. Allowed reread company states results very positive. Looking to sell outright on approval. RPRX Proellex Phase 3 Uterine fibroids

ELAN bapineuzimab ph 3 no data expected until late 2010. enough cash to last only until mid 2010

[ghmm]

Here is the template but if someone comes up with a better one please feel free to use it. Everything below the following
=========================

Late Stage Products looking for a home

Criteria
1. Unparterned
2. Not enough cash to bring the product to market
3. Lets say at least started Phase 3 trials
4. Its on a product basis so if company a has 2 unparterned Phase 3 products and not enough cash then an entry for each would be appropriate

 
   Stock  Product          Stage                   Comments   
   -----  ---------------  ---------------------   -----------------------------   
   NTII   Viprinex         Phase 3                 Interim analysis January '09.  Stroke Drug, high chance of failure.   
   BPAX   Libigel          Phase 3 ~2010 Submit    Adequate Safety?   
   EPIX   Vasovist         PDUFA 12/30/08          FDA initially rejected saying 2 more studies needed.  Allowed reread company states   
                                                   results very positive.  Looking to sell outright on approval.   
   RPRX   Proellex         Phase 3                 Uterine fibroids   
 

-----
1. Reply to this post copying all the text
2. Please put [ pre ] at the begining of the table without surrounding spaces.
3. Please put [ /pre ] at the end of the table without surrounding spaces.